Maxim Group analyst Jason McCarthy has maintained their bullish stance on CAPR stock, giving a Buy rating yesterday.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Jason McCarthy has given his Buy rating due to a combination of factors, including the strategic value of deramiocel and the potential resolution of the NS Pharma dispute. He views the lawsuit as a calculated effort by Capricor to regain or clarify commercial rights to a late-stage, potentially life‑saving Duchenne muscular dystrophy therapy, where clinical data indicate a pronounced reduction in cardiac decline.
McCarthy’s base case assumes Capricor secures an injunction that allows commercialization to proceed despite ongoing legal proceedings, with broader public health and “America First” policy considerations likely favoring patient access. While acknowledging legal and execution risks, he believes the downside is partially reflected in the share price, and he maintains a favorable risk‑reward profile with an unchanged $50 price target, supported by deramiocel’s differentiated profile and the sizeable unmet need in DMD.
In another report released yesterday, Roth MKM also maintained a Buy rating on the stock with a $43.00 price target.
CAPR’s price has also changed dramatically for the past six months – from $6.200 to $31.900, which is a 414.52% increase.